Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""SALMETEROL"" wg kryterium: Temat


Tytuł :
Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis.
Autorzy :
Jiang P; Department of Pediatrics, Minhang Hospital, Fudan University, Shanghai 201100, China.
Zhao L; Department of Pediatrics, Minhang Hospital, Fudan University, Shanghai 201100, China.
Yao Z; Department of Pediatrics, Minhang Hospital, Fudan University, Shanghai 201100, China.
Pokaż więcej
Źródło :
Journal of comparative effectiveness research [J Comp Eff Res] 2021 Dec; Vol. 10 (17), pp. 1283-1289. Date of Electronic Publication: 2021 Oct 20.
Typ publikacji :
Journal Article
MeSH Terms :
Asthma*/drug therapy
Fluticasone-Salmeterol Drug Combination*/therapeutic use
Anti-Asthmatic Agents/*therapeutic use
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Adolescent ; Child ; Drug Combinations ; Humans ; Prospective Studies
Czasopismo naukowe
Tytuł :
Determination of salmeterol, α-hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS.
Autorzy :
Sakellariou P; Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Resarch 'Demokritos', Maroussi, Greece.; Faculty of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
Petrou M; Cyprus Anti-Doping Authority, Nicosia, Cyprus.; University of Nicosia, Nicosia, Cyprus.
Lyris E; Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Resarch 'Demokritos', Maroussi, Greece.
Tsivou M; Dopingkontroll-Labor, Chemical Analytics Seibersdorf Labor GmbH, Seibersdorf, Austria.
Fragkaki A; Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Resarch 'Demokritos', Maroussi, Greece.
Kiousi P; Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Resarch 'Demokritos', Maroussi, Greece.
Angelis YS; Doping Control Laboratory of Athens, Institute of Biosciences and Applications, National Centre for Scientific Resarch 'Demokritos', Maroussi, Greece.
Pistos C; Department of Chemistry, West Chester University of Pennsylvania, West Chester, PA, USA.
Pokaż więcej
Źródło :
Biomedical chromatography : BMC [Biomed Chromatogr] 2021 Aug; Vol. 35 (8), pp. e5114. Date of Electronic Publication: 2021 Apr 11.
Typ publikacji :
Journal Article
MeSH Terms :
Doping in Sports*
Fluticasone*/blood
Fluticasone*/urine
Salmeterol Xinafoate*/blood
Salmeterol Xinafoate*/urine
Albuterol/*analogs & derivatives
Chromatography, High Pressure Liquid/*methods
Albuterol/blood ; Humans ; Linear Models ; Reproducibility of Results ; Sensitivity and Specificity ; Substance Abuse Detection
Czasopismo naukowe
Tytuł :
Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Autorzy :
Jessen S; Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
Becker V; Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark.
Rzeppa S; Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway.
Backer V; Centre for Physical Activity Research, Rigshospitalet and Copenhagen University, Copenhagen, Denmark.
Bengtsen KH; Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
Hullstein I; Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway.
Dehnes Y; Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway.
Hostrup M; Section of Integrative Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło :
Drug testing and analysis [Drug Test Anal] 2021 Apr; Vol. 13 (4), pp. 747-761. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji :
Controlled Clinical Trial; Journal Article
MeSH Terms :
Adrenergic beta-2 Receptor Agonists/*pharmacokinetics
Albuterol/*analogs & derivatives
Salmeterol Xinafoate/*pharmacokinetics
Substance Abuse Detection/*methods
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/analysis ; Adult ; Albuterol/analysis ; Albuterol/pharmacokinetics ; Chromatography, High Pressure Liquid ; Doping in Sports/prevention & control ; Dry Powder Inhalers ; Humans ; Male ; Salmeterol Xinafoate/administration & dosage ; Salmeterol Xinafoate/analysis ; Tandem Mass Spectrometry ; Young Adult
Czasopismo naukowe
Tytuł :
The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
Autorzy :
Tashkin DP; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Ohar JA; Department of Internal Medicine, Section of Pulmonary, Critical Care, Allergy and Immunologic Medicine at Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Koltun A; Viatris/Mylan Inc., Canonsburg, PA, USA.
Allan R; Viatris/Mylan Pharma UK Ltd., UK.
Ward JK; Viatris/Mylan Pharma UK Ltd., UK.
Pokaż więcej
Źródło :
Pulmonary medicine [Pulm Med] 2021 Mar 17; Vol. 2021, pp. 8881895. Date of Electronic Publication: 2021 Mar 17 (Print Publication: 2021).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Asthma*/drug therapy
Asthma*/epidemiology
Asthma*/physiopathology
Bronchodilator Agents*/pharmacokinetics
Bronchodilator Agents*/therapeutic use
Fluticasone-Salmeterol Drug Combination*/pharmacokinetics
Fluticasone-Salmeterol Drug Combination*/therapeutic use
Glucocorticoids*/pharmacokinetics
Glucocorticoids*/therapeutic use
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/epidemiology
Pulmonary Disease, Chronic Obstructive*/physiopathology
Administration, Inhalation ; Drugs, Generic/pharmacokinetics ; Drugs, Generic/therapeutic use ; Health Services Needs and Demand/statistics & numerical data ; Humans ; Nebulizers and Vaporizers ; Powders/pharmacokinetics ; Powders/therapeutic use ; Practice Guidelines as Topic ; Standard of Care ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Autorzy :
O'Shea O; School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland.
Stovold E; Cochrane Airways, Population Health Research Institute, St George's, University of London, London, UK.
Cates CJ; Cochrane Airways, Population Health Research Institute, St George's, University of London, London, UK.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2021 Apr 14; Vol. 4. Cochrane AN: CD007694. Date of Electronic Publication: 2021 Apr 14.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Anti-Asthmatic Agents/*adverse effects
Asthma/*drug therapy
Formoterol Fumarate/*administration & dosage
Glucocorticoids/*adverse effects
Salmeterol Xinafoate/*administration & dosage
Administration, Inhalation ; Adolescent ; Adult ; Anti-Asthmatic Agents/administration & dosage ; Asthma/mortality ; Beclomethasone/administration & dosage ; Beclomethasone/adverse effects ; Bronchodilator Agents/administration & dosage ; Bronchodilator Agents/adverse effects ; Budesonide/administration & dosage ; Budesonide/adverse effects ; Child ; Chronic Disease ; Drug Therapy, Combination/adverse effects ; Fluticasone/administration & dosage ; Fluticasone/adverse effects ; Formoterol Fumarate/adverse effects ; Glucocorticoids/administration & dosage ; Humans ; Mometasone Furoate/administration & dosage ; Mometasone Furoate/adverse effects ; Randomized Controlled Trials as Topic ; Salmeterol Xinafoate/adverse effects
Czasopismo naukowe
Tytuł :
Investigation of spectrophotometric simultaneous absorption of Salmeterol and Fluticasone in Seroflo spray by continuous wavelet transform and radial basis function neural network methods.
Autorzy :
Valizadeh M; Department of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran. Electronic address: .
Sohrabi M; Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Ameri Braki Z; Department of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Rashidi R; Faculty of Civil, Water and Environmental engineering, Shahid Beheshti University of Iran, Tehran, Iran.
Pezeshkpur M; Department of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Pokaż więcej
Źródło :
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2021 Dec 15; Vol. 263, pp. 120192. Date of Electronic Publication: 2021 Jul 17.
Typ publikacji :
Journal Article
MeSH Terms :
Neural Networks, Computer*
Wavelet Analysis*
Fluticasone ; Salmeterol Xinafoate ; Spectrophotometry
Czasopismo naukowe
Tytuł :
[Determination of the enantiomers of salmeterol xinafoate in salmeterol fluticasone powder inhalant by chiral nonaqueous capillary electrophoresis].
Autorzy :
Zhang X; Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Institute of Life Science and Green Development, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, China.
Dong M; Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Institute of Life Science and Green Development, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, China.
Xu Y; Tianjin Alta Scientific Co., Ltd., Tianjin 300457, China.
Wang L; Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Institute of Life Science and Green Development, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, China.
Qiao X; Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Institute of Life Science and Green Development, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, China.
Pokaż więcej
Źródło :
Se pu = Chinese journal of chromatography [Se Pu] 2021 Dec; Vol. 39 (12), pp. 1355-1361.
Typ publikacji :
Journal Article
MeSH Terms :
Electrophoresis, Capillary*
Fluticasone ; Powders ; Reproducibility of Results ; Salmeterol Xinafoate ; Stereoisomerism
Czasopismo naukowe
Tytuł :
A cautionary tale of multiple-dose drug products: Fluticasone and salmeterol combination inhaler waste.
Autorzy :
Aeng ESY; Pharmacy Department, Fraser Health Authority, Surrey, British Columbia, Canada.
Dhaliwal MM; Pharmacy Department, Fraser Health Authority, Surrey, British Columbia, Canada.
Tejani AM; Pharmacy Department, Fraser Health Authority, Surrey, British Columbia, Canada.
Pokaż więcej
Źródło :
Journal of evaluation in clinical practice [J Eval Clin Pract] 2020 Dec; Vol. 26 (6), pp. 1699-1702. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Asthma*/drug therapy
Bronchodilator Agents*/therapeutic use
Fluticasone*/therapeutic use
Salmeterol Xinafoate*/therapeutic use
Administration, Inhalation ; Canada ; Drug Combinations ; Humans ; Nebulizers and Vaporizers ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs.
Autorzy :
Ewing P; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Oag S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lundqvist A; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Stomilovic S; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Stellert I; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Antonsson M; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Nunes SF; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Andersson PU; Inhalation Product Development, AstraZeneca, Gothenburg, Sweden.
Tehler U; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Sjöberg C; Flexura AB, Sweden.; Inhalation Sciences AB, Sweden.
Péterffy A; Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Gerde P; Inhalation Sciences AB, Sweden.; Environmental Medicine Karolinska Institutet, Sweden.
Pokaż więcej
Źródło :
Journal of aerosol medicine and pulmonary drug delivery [J Aerosol Med Pulm Drug Deliv] 2021 Aug; Vol. 34 (4), pp. 231-241. Date of Electronic Publication: 2020 Nov 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Dry Powder Inhalers*
Respiration, Artificial*
Administration, Inhalation ; Animals ; Fluticasone ; Fluticasone-Salmeterol Drug Combination ; Lung ; Salmeterol Xinafoate ; Swine
Czasopismo naukowe
Tytuł :
Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma.
Autorzy :
Ortega VE; Department of Internal Medicine, Section for Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: .
Daya M; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Szefler SJ; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Bleecker ER; Department of Internal Medicine, Division of Genetics, Genomics, and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
Chinchilli VM; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Phipatanakul W; Division of Pediatric Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Mauger D; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Martinez FD; Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, AZ, USA.
Herrera-Luis E; Department of Biochemistry, La Laguna, Tenerife, Spain; Microbiology, Cell Biology, and Genetics, La Laguna, Tenerife, Spain; Genomics and Health Group, La Laguna, Tenerife, Spain; Universidad de La Laguna, La Laguna, Tenerife, Spain.
Pino-Yanes M; Department of Biochemistry, La Laguna, Tenerife, Spain; Microbiology, Cell Biology, and Genetics, La Laguna, Tenerife, Spain; Genomics and Health Group, La Laguna, Tenerife, Spain; Universidad de La Laguna, La Laguna, Tenerife, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
Hawkins GA; Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Ampleford EJ; Department of Internal Medicine, Section for Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Kunselman SJ; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Cox C; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Bacharier LB; Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA.
Cabana MD; Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Cardet JC; Department of Internal Medicine, Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Castro M; Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Denlinger LC; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Eng C; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Fitzpatrick AM; Department of Pediatrics, Emory University, Atlanta, GA, USA.
Holguin F; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Hu D; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Jackson DJ; Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA.
Jarjour N; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Kraft M; Department of Internal Medicine, Division of Genetics, Genomics, and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
Krishnan JA; Breathe Chicago Center, Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois, Chicago, IL, USA.
Lazarus SC; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Lemanske RF Jr; Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA.
Lima JJ; Center for Pharmacogenomics and Translational Research, Nemours Children's Health System, Jacksonville, FL, USA.
Lugogo N; Department of Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA.
Mak A; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Moore WC; Department of Internal Medicine, Section for Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Naureckas ET; Department of Medicine, University of Chicago, Chicago, IL, USA.
Peters SP; Department of Internal Medicine, Section for Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Pongracic JA; Department of Pediatrics, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Sajuthi SP; Center for Genes, Environment, and Health, Department of Pediatrics, National Jewish Health, Denver, CO, USA.
Seibold MA; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA; Center for Genes, Environment, and Health, Department of Pediatrics, National Jewish Health, Denver, CO, USA.
Smith LJ; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Solway J; Department of Medicine, University of Chicago, Chicago, IL, USA.
Sorkness CA; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Wenzel S; Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
White SR; Department of Medicine, University of Chicago, Chicago, IL, USA.
Burchard EG; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Barnes K; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Meyers DA; Department of Internal Medicine, Division of Genetics, Genomics, and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
Israel E; Department of Pulmonary and Critical Care Medicine and Allergy and Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Wechsler ME; Department of Medicine, National Jewish Health, Denver, CO, USA.
Pokaż więcej
Corporate Authors :
NHLBI AsthmaNet
Źródło :
The Lancet. Child & adolescent health [Lancet Child Adolesc Health] 2021 Dec; Vol. 5 (12), pp. 862-872. Date of Electronic Publication: 2021 Nov 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Blacks*
Pharmacogenomic Testing*
Adrenal Cortex Hormones/*therapeutic use
Asthma/*drug therapy
Bronchodilator Agents/*therapeutic use
Fluticasone/*therapeutic use
Salmeterol Xinafoate/*therapeutic use
Administration, Inhalation ; Adolescent ; Adult ; Asthma/ethnology ; Child ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis.
Autorzy :
Zhou XJ; Department of Paediatrics, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, China.
Qin Z
Lu J
Hong JG
Pokaż więcej
Źródło :
Chinese medical journal [Chin Med J (Engl)] 2021 Nov 15; Vol. 134 (24), pp. 2954-2961. Date of Electronic Publication: 2021 Nov 15.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Anti-Asthmatic Agents*/therapeutic use
Asthma*/drug therapy
Acetates ; Administration, Inhalation ; Adolescent ; Adrenal Cortex Hormones/therapeutic use ; Albuterol/therapeutic use ; Child ; Cyclopropanes ; Drug Therapy, Combination ; Fluticasone/therapeutic use ; Humans ; Quinolines ; Salmeterol Xinafoate/therapeutic use ; Sulfides
Czasopismo naukowe
Tytuł :
Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation.
Autorzy :
Sadiq MW; Clinical and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Safety Sciences, AstraZeneca, Gothenburg, Sweden.; R&D, AstraZeneca, Gothenburg, Sweden.
Holz O; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.; Biomedical Research in End-stage and Obstructive Lung Disease (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
Ellinghusen BD; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Faulenbach C; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Müller M; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Badorrek P; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
Eriksson UG; Clinical and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.; Clinical Pharmacology and Safety Sciences, AstraZeneca, Gothenburg, Sweden.; R&D, AstraZeneca, Gothenburg, Sweden.
Fridén M; Drug Metabolism and Pharmacokinetics, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, AstraZeneca, Gothenburg, Sweden.; Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden.
Stomilovic S; Drug Metabolism and Pharmacokinetics, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, AstraZeneca, Gothenburg, Sweden.; Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Lundqvist AJ; Drug Metabolism and Pharmacokinetics, AstraZeneca, Gothenburg, Sweden.; Research and Early Development, AstraZeneca, Gothenburg, Sweden.; Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Hohlfeld JM; Division of Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.; Biomedical Research in End-stage and Obstructive Lung Disease (BREATH), German Center for Lung Research (DZL), Hannover, Germany.; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Pokaż więcej
Źródło :
British journal of pharmacology [Br J Pharmacol] 2021 Nov; Vol. 178 (22), pp. 4440-4451. Date of Electronic Publication: 2021 Aug 11.
Typ publikacji :
Journal Article
MeSH Terms :
Pharmaceutical Preparations*
Albuterol ; Fluticasone ; Humans ; Lung ; Salmeterol Xinafoate
Czasopismo naukowe
Tytuł :
Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Autorzy :
Huang TM; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Kuo KC; Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Wang YH; Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Wang CY; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Lai CC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan. .
Wang HC; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. .
Chen L; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Pokaż więcej
Corporate Authors :
On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Sep 25; Vol. 20 (1), pp. 706. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Mycobacterium tuberculosis*
Adrenal Cortex Hormones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Tuberculosis/*epidemiology
Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Budesonide, Formoterol Fumarate Drug Combination/administration & dosage ; Budesonide, Formoterol Fumarate Drug Combination/adverse effects ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Fluticasone-Salmeterol Drug Combination/adverse effects ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Propensity Score ; Risk Factors ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł :
Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization.
Autorzy :
Ainali NM; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Xanthopoulou E; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Michailidou G; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Zamboulis A; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Bikiaris DN; Laboratory of Polymer Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2020 Aug 26; Vol. 25 (17). Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Journal Article
MeSH Terms :
Fluticasone*/chemistry
Fluticasone*/pharmacokinetics
Fluticasone*/pharmacology
Salmeterol Xinafoate*/chemistry
Salmeterol Xinafoate*/pharmacokinetics
Salmeterol Xinafoate*/pharmacology
Administration, Inhalation ; Capsules ; Delayed-Action Preparations/chemistry ; Delayed-Action Preparations/pharmacokinetics ; Delayed-Action Preparations/pharmacology ; Humans ; Particle Size ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/metabolism
Czasopismo naukowe
Tytuł :
Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results.
Autorzy :
Wing K; Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Williamson E; Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Carpenter JR; Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Wise L; Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Schneeweiss S; Department of Epidemiology, Harvard Medical School, Boston, MA, USA.; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Smeeth L; Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Quint JK; National Heart and Lung Institute, Imperial College London, London, UK.
Douglas I; Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2021 Aug; Vol. 25 (51), pp. 1-70.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Pulmonary Disease, Chronic Obstructive*/drug therapy
Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Cohort Studies ; Humans ; Salmeterol Xinafoate/therapeutic use
Czasopismo naukowe
Tytuł :
Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).
Autorzy :
Vaz Fragoso CA; Veterans Affairs (VA) Connecticut Healthcare System, West Haven, CT, USA; Yale University School of Medicine, Department of Internal Medicine, New Haven, CT, USA. Electronic address: .
Gill TM; Yale University School of Medicine, Department of Internal Medicine, New Haven, CT, USA.
Leo-Summers LS; Yale University School of Medicine, Department of Internal Medicine, New Haven, CT, USA.
Van Ness PH; Yale University School of Medicine, Department of Internal Medicine, New Haven, CT, USA.
Pokaż więcej
Źródło :
Respiratory medicine [Respir Med] 2019 May; Vol. 151, pp. 27-34. Date of Electronic Publication: 2019 Mar 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Bronchodilator Agents/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Pulmonary Disease, Chronic Obstructive/*mortality
Aged ; Cardiovascular Diseases/mortality ; Female ; Fluticasone/therapeutic use ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Pneumonia/epidemiology ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Salmeterol Xinafoate/therapeutic use ; Severity of Illness Index ; Spirometry
Czasopismo naukowe
Tytuł :
孟鲁司特钠片联合沙美特罗替卡松吸入气雾剂 治疗老年中重度支气管哮喘有效性和安全性的 系统评价.
Autorzy :
郑子恢
潘慧杰
张亚同
马 琳
李文英
原 涵
金鹏飞
Pokaż więcej
Alternatywny tytuł :
Systematic Review of Efficacy and Safety of Montelukast Sodium Tablets Combined with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol in the Treatment of Moderate and Severe Bronchial Asthma in the Elderly.
Źródło :
Evaluation & Analysis of Drug-Use in Hospitals of China. 2021, Issue 10, p1227-1240. 9p.
Czasopismo naukowe
Tytuł :
Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β 2-Adrenergic Receptor Agonists.
Autorzy :
Szlenk CT; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Gc JB; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Natesan S; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington .
Pokaż więcej
Źródło :
Molecular pharmacology [Mol Pharmacol] 2021 Oct; Vol. 100 (4), pp. 406-427. Date of Electronic Publication: 2021 Aug 01.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Adrenergic beta-2 Receptor Agonists/*chemistry
Adrenergic beta-2 Receptor Agonists/*metabolism
Cell Membrane/*metabolism
Molecular Docking Simulation/*methods
Albuterol/chemistry ; Albuterol/metabolism ; Binding Sites/physiology ; Delayed-Action Preparations/chemistry ; Delayed-Action Preparations/metabolism ; Formoterol Fumarate/chemistry ; Formoterol Fumarate/metabolism ; Humans ; Protein Binding/physiology ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Salmeterol Xinafoate/chemistry ; Salmeterol Xinafoate/metabolism
Czasopismo naukowe
Tytuł :
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β 2 -Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β 2 -Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
Autorzy :
Wang MT; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan. Electronic address: .
Lai JH; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Huang YL; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan; Department of Pharmacy, En Chu Kong Hospital, New Taipei City, Taiwan.
Liou JT; Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, National Defense Medical Center, Taipei, Taiwan.
Cheng SH; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Lin CW; College of Pharmacy, University of Minnesota-Duluth, Duluth, MN, USA.
Pan HY; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Hsu YJ; Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Graduate Institutes of Medical Sciences and Biochemistry, National Defense Medical Cente, Taipei, Taiwan.
Tsai CL; Division of Pulmonary and Critical Care, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address: .
Pokaż więcej
Źródło :
Chest [Chest] 2021 Oct; Vol. 160 (4), pp. 1255-1270. Date of Electronic Publication: 2021 May 21.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Glucocorticoids/*therapeutic use
Muscarinic Antagonists/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Aged ; Beclomethasone/therapeutic use ; Benzyl Alcohols/therapeutic use ; Budesonide, Formoterol Fumarate Drug Combination/therapeutic use ; Chlorobenzenes/therapeutic use ; Cohort Studies ; Comparative Effectiveness Research ; Disease Progression ; Drug Combinations ; Female ; Fluticasone-Salmeterol Drug Combination/therapeutic use ; Formoterol Fumarate/therapeutic use ; Glycopyrrolate/analogs & derivatives ; Glycopyrrolate/therapeutic use ; Humans ; Indans/therapeutic use ; Male ; Pneumonia/epidemiology ; Propensity Score ; Proportional Hazards Models ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinolones/therapeutic use ; Quinuclidines/therapeutic use
Czasopismo naukowe
Tytuł :
Comparison of the effect of fluticasone combined with salmeterol and fluticasone alone in the treatment of pediatric asthma.
Autorzy :
Cao H; Pediatric Ward, the Second Affiliated Hospital of Nantong University, Nantong City, China.
Gu J; Department of Radiology, the Second Affiliated Hospital of Nantong University, Nantong City, China.
Dai J; Pediatric Ward, the Second Affiliated Hospital of Nantong University, Nantong City, China.
Yang G; Pediatric Ward, the Second Affiliated Hospital of Nantong University, Nantong City, China.
Tang H; Pediatric Ward, the Second Affiliated Hospital of Nantong University, Nantong City, China.
Ding A; Department of Nursing, the Second Affiliated Hospital of Nantong University, Nantong City, China - .
Pokaż więcej
Źródło :
Minerva pediatrics [Minerva Pediatr (Torino)] 2021 Oct; Vol. 73 (5), pp. 452-459. Date of Electronic Publication: 2021 May 14.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Asthma*/drug therapy
Bronchodilator Agents*/adverse effects
Androstadienes/adverse effects ; Child ; Drug Combinations ; Fluticasone/adverse effects ; Formoterol Fumarate/therapeutic use ; Humans ; Salmeterol Xinafoate/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies